Biotech Startups

Actym Therapeutics engineers bacteria as a delivery system for therapeutics targeting cancer and fibrotic disease. Its approach uses engineered S. Typhimurium to systemically administer and locally produce multiple therapeutic payloads at the disease site to reduce systemic toxicity.

1 investor

AcuamarkDx is a molecular diagnostics company developing early cancer detection technology using proprietary qPCR and machine learning-driven assays for cancer screening and recurrence monitoring. It aims to make frequent, recurring cancer signal monitoring a standard part of primary care.

1 investor

Kubota Vision develops pharmaceutical drugs and medical devices to preserve and restore vision for patients with eye diseases worldwide. The company is a subsidiary of Kubota Pharmaceutical and focuses on treating blindness.

1 investor

1 investor

Acumen Pharmaceuticals is developing treatments for Alzheimer's disease and other neurodegenerative diseases, focusing on understanding and targeting amyloid beta oligomers in neurodegeneration.

1 investor

1 investor

1 investor

ACVC Partners is a venture capital firm that partners with leading corporations to invest in deep technology startups. The firm combines corporate partner expertise and resources with its own investment capabilities to support early-stage technology companies.

1 investor

ACX develops bioengineered solutions for pest control in agriculture, replacing synthetic chemicals with precision biocides. The company serves crop producers and aims to enhance food security while reducing chemical dependence and promoting biodiversity.

1 investor

Acxel develops digital microfluidics platforms for biochemical experiments, using thin-film semiconductor processes and active-matrix technologies such as Active Pixel Lab-on-Chip (AP-LOC), AM-EWOD, and AM-DMF for high-throughput, parallel, precise microdroplet manipulation. It offers custom digital microfluidics solutions with mass-production support for drug development and basic biology research.

1 investor

Adalid Sciences engineers lipid nanoparticles to improve the delivery and efficacy of gene therapies, targeting better therapeutic outcomes with reduced side effects. The company serves developers of nucleic acid medicines and therapeutic partners seeking advanced drug delivery solutions.

1 investor

Adaptam Therapeutics develops antibody-based cancer immunotherapies, including antibody-drug conjugates and bispecific antibodies, that target the immunosuppressive myeloid tumor microenvironment via novel targets such as glycan-binding proteins and Siglecs. A spin-off from CIC bioGUNE, the company serves oncology patients and is developing first-in-class therapies for multiple cancer indications.

1 investor

Adare Pharma Solutions is a CDMO (contract development and manufacturing organization) and pharma services provider serving the biopharma industry with manufacturing, research and development, and patient support capabilities.

1 investor

1 investor

Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs. The company translates scientific innovation into clinically differentiated medicines for patients with advanced solid tumors and other cancer types.

1 investor

Addimmune develops gene therapy treatments for HIV, specifically AGT103-T, a first-in-class functional cure candidate that modifies patient immune cells to recognize and eliminate HIV-infected cells. The company is based in Rockville, Maryland and targets individuals living with HIV.

1 investor

Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team. Its work centers on drug discovery and portfolio development in the life sciences.

1 investor

Adenocyte develops LINFU (Low Intensity Non-Focused Ultrasound), a minimally invasive ultrasound technology for routine screening of the pancreas to detect pancreatic dysplasia and early-stage pancreatic cancer. The company serves clinical cancer screening for elevated- and average-risk patients, with laboratories in Haifa and Jerusalem and clinical development at the Technion and North American screening centers.

1 investor

Adeptrix develops the exoBAMS platform, using antibody-based immunoaffinity capture of extracellular vesicles combined with MALDI mass spectrometry to profile proteins, lipids, metabolites and other molecules from a single blood sample. It provides custom assay development and bioanalytical services to researchers for biomarker discovery, disease-signature analysis, and translational research in oncology, neurology, and other disease areas.

1 investor

Adesis provides contract chemistry services, including custom synthesis and process development for complex molecules, high-purity monomers, deuterated compounds, peptides, oligonucleotides, and custom linkers. It serves pharmaceutical, medical device, and specialty research programs, with production facilities in the US and Ireland.

1 investor

Adjutec Pharma develops novel antibiotic "resistance breakers" intended as a last line of defence against antibiotic-resistant infections. The company operates in the pharmaceutical and biotech industry.

1 investor

ADMA Biologics develops and manufactures specialty plasma-derived biologic products, including immune globulin therapies, for immune-compromised patients and others at risk of certain infections. The company operates a vertically integrated, end-to-end manufacturing process using a proprietary microneutralization assay and also offers contract manufacturing services.

1 investor

Adovate is a life science company developing a pipeline of adenosine analog compounds, with research and laboratory work focused on medicinal chemistry and pharmaceutical development. It operates in the biotech and pharmaceutical industry.

1 investor

Structure-based small-molecule drug design targeting protein aggregation diseases.

1 investor